A small-cap stock I think could be a growth champion in 2020

This small-cap growth stock has more than doubled its revenues in 2019, and I think 2020 could be a take-off year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In March 2019, my Motley Fool colleague Paul Summers told us he’d sold his stake in Science in Sport (LSE: SIS), as he’d been disappointed by the firm’s earlier promise.

It looks like Paul got it right. Although SiS shares perked up a little a few months later, they’ve crashed back and declined around 20% since the time he was selling.

SIS is one of those ‘jam tomorrow’ investments that could have great long-term growth prospects, but are as-yet-unprofitable and are still in their cash-burn phase. In late 2017, I’d been cautiously optimistic when the shares were at 72p. Two years on, at 42.8p, it’s clear that would have been a bad time to buy.

Wait for profit?

Many would say wait until the profits start to come in. Yes, you’ll almost certainly miss the biggest potential gains as it’s very likely that a growth share price will have appreciated by the time the firm is making money. But you’ll greatly minimise your chances of holding a crash-and-burn dud.

Yet pondering the excitement of finding a growth stock in its early stages for those who don’t mind the risk, I’m still thinking SiS could turn into that big winner.

And shares in the sports nutritionist blipped up a couple of percent on Tuesday morning in response to a full-year update, ahead of results due on 18 March.

The company described 2019 as having been a landmark year, “representing the first full year of ownership of the PhD brand following its acquisition in December 2018,” and said it “expects to report total sales for 2019 of £50.5m.”

Strong growth

That’s way ahead of 2018’s £21.3m, and apparently represents strong growth for the SiS brand in addition to the PhD acquisition. E-commerce sales (which is an essential part of any new business like this) gained 34% to £16.1m, a significant proportion of total sales.

Getting the company’s brands into Lidl, Aldi and Tesco has also helped lift UK retail sales by 8%, and international retail is up 44% after a major launch in Saudi Arabia.

That all sounds great, so why aren’t I rushing to hit the buy button? It’s all about profits and cash. And there are no real profits forecast before 2021 (not counting the mere £20k suggested for 2020).

At the halfway stage in 2019, SiS reported a gross profit of £11.15m with a gross margin of 44.8%. But it was far from converting that to cash to put into investors’ pockets, as it translated to a £0.6m underlying operating loss.

The cash

At 30 June 2019, we saw cash and equivalents of £5.03m, down from £8m six months previously, and from £10.66m a year prior at H1 2018. At that rate, it could run out before the end of 2020, unless SiS makes great progress in at least breaking even on the cash flow front as early as possible.

My feeling, in line with Paul’s, is that SiS might need a new cash call in 2020 to raise more capital. That would mean dilution, and probably a share price fall.

With my Sirius Minerals failure fresh in my memory, I wouldn’t buy SiS right now — but I’ll think again when those results are out and I can reassess the cash situation.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft owns shares of Sirius Minerals. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A pastel colored growing graph with rising rocket.
Investing Articles

How much passive income could I make for every £1,000 invested in Aviva shares?

Even a relatively small investment in Aviva shares could generate much greater passive income, particularly if the dividends are reinvested…

Read more »

Close-up of British bank notes
Investing Articles

I’m considering 100 shares in this FTSE 250 gem to aim for £300 a month in dividends

Mark Hartley outlines why a lesser-known banking stock from the FTSE 250's worth considering for an income portfolio in 2024.

Read more »

Investing Articles

History suggests these UK shares might soar if interest rates are cut in August

Some UK shares could rocket if interest rates fall from its 5.25% high next month. And there's one our writer…

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Investing Articles

Here’s why H1 results could boost the AstraZeneca share price

The AstraZeneca share price has been a success story in the past five years. With H1 results due, can it…

Read more »

Investing Articles

£17,365 in savings? Here’s how I’d use it to target a £6,700-a-month passive income

Here's how a lump sum investment could pave the way for me to make a four-figure monthly passive income in…

Read more »

Investing Articles

Down more than 10% in 6 months, Fools are backing these 5 UK stocks to reverse that – and then some! – by 2025

Some of our UK free-site writers have put forward their candidates for turnaround stocks!

Read more »

Investing Articles

Down 23%! Should I buy more CrowdStrike shares for my Stocks and Shares ISA?

Sometimes bad news can be good news for long-term investors. But is that the case for CrowdStrike in relation to…

Read more »

Investing Articles

2 UK shares near 52-week lows I’m considering snapping up

These UK shares are loitering near, or at, 52-week lows. Are these prime opportunities for our writer to boost her…

Read more »